CAMMARATA, Edoardo et al. Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits. Dermatology Practical & Conceptual, [S. l.], v. 15, n. 3, p. 5845, 2025. DOI: 10.5826/dpc.1503a5845. Disponível em: https://dpcj.org/index.php/dpc/article/view/5845.. Acesso em: 12 feb. 2026.